% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@INPROCEEDINGS{Stegmayr:825276,
      author       = {Stegmayr, Carina and Willuweit, Antje and Schöneck,
                      Michael and Filss, Christian and Shah, N. J. and Coenen,
                      Heinrich Hubert and Ermert, Johannes and Langen, Karl-Josef},
      title        = {{R}eproducibility of
                      {O}-(2-[{F}-18]fluoroethyl)-{L}-tyrosine kinetics in brain
                      tumors and influence of dexamethasone therapy: {A} {PET}
                      study in rat gliomas},
      reportid     = {FZJ-2016-07747},
      year         = {2015},
      abstract     = {Objectives: Previous studies have shown that uptake
                      kinetics of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) in brain
                      tumors correlates with the grade of malignancy. This study
                      investigates the reproducibility of FET kinetics in rat
                      gliomas and the influence of the commonly used dexamethasone
                      (Dex) therapy.Methods: Tumor cells were implanted in the
                      striatum of 31 Fischer rats (15 rats with 9L gliosarcoma; 16
                      with F98 glioma). Dynamic FET PET (0-60 min post injection,
                      p.i.) was performed after 10 days of tumor growth (baseline)
                      and 48 h later (control) using animal PET (Inveon). Group 1
                      (n= 8 for 9L; n=10 for F98) received no treatment and group
                      2 (n= 7 for 9L; n=6 for F98) was injected with 8 mg/kg Dex
                      intraperitoneal after baseline PET plus 4 mg/kg Dex 24 h and
                      1 h before control PET. Tumor to brain ratios (TBR) (18-60
                      min p.i.) and the slope of a linear fit of the time activity
                      curve (15 to 60 min p.i.) were determined.Results: The two
                      tumor models showed different FET kinetics (9L slope: +0.17
                      ± 0.12 SUV/h; F98 slope: +0.76 ± 0.09 SUV/h; p < 0.001)
                      and different TBR (9L: 1.87 ± 0.07; F98: 1.98 ± 0.07; p =
                      0.005). Both models showed no significant changes of slope
                      in both groups. In all untreated gliomas, TBR slightly
                      increased (9L: 1.87 ± 0.07 vs. 1.95 ± 0.08, p < 0.001;
                      F98: 1.98 ± 0.07 vs. 2.04 ± 0.06, p = 0.002) from baseline
                      to control scan, while the TBR in all Dex treated gliomas
                      decreased (9L: 1.86 ± 0.03 vs. 1.65 ± 0.08, p < 0.001;
                      F98: 1.99 ± 0.10 vs. 1.89 ± 0.15, p = 0.025). This
                      decrease is due to enhanced FET accumulation in normal brain
                      tissue after Dex treatment.Conclusions: FET kinetics in
                      cerebral gliomas show high reproducibility and little
                      interference with Dex therapy. Thus, changes of FET kinetics
                      may be considered reliable indicators of biological
                      reactions occurring in brain tumors during
                      radio/chemotherapy.},
      month         = {May},
      date          = {2015-05-26},
      organization  = {21st International Symposium on
                       Radiopharmaceutical Sciences, Columbia
                       (USA), 26 May 2015 - 31 May 2015},
      subtyp        = {Plenary/Keynote},
      cin          = {INM-4 / INM-5},
      cid          = {I:(DE-Juel1)INM-4-20090406 / I:(DE-Juel1)INM-5-20090406},
      pnm          = {572 - (Dys-)function and Plasticity (POF3-572)},
      pid          = {G:(DE-HGF)POF3-572},
      typ          = {PUB:(DE-HGF)24},
      url          = {https://juser.fz-juelich.de/record/825276},
}